Efficacy of baloxavir marboxil as a prophylactic against influenza among in-patients and analysis of influenza virus mutations in their isolates at a Japanese hospital during the 2023–2024 flu season
According to our results, Baloxavir represents an effective prophylactic against influenza for hospitalized in-patients. However, patients with genetic mutations related to decreased susceptibility to influenza, such as I38T variant, should nevertheless exercise higher levels of caution-particularly around children.
Authors
- Katsuichiro Okazaki
- Hayakazu Sumida (ORCID: https://orcid.org/0000-0003-0531-559X)
- Eisei Kondo
- Tomohiro Oishi (ORCID: https://orcid.org/0000-0003-3842-3044)
- Yuichi Ninomiya (ORCID: https://orcid.org/0000-0002-1618-9739)
- M Kobayashi
- Shota Uesugi (ORCID: https://orcid.org/0000-0001-6470-7804)
- Yuka Ikeda
- Daisuke Yoshioka (ORCID: https://orcid.org/0000-0002-5574-9495)
- Hideho Wada
- Akihide FUJII
- Zyunko Morihara
Institutions
- Kawasaki Medical School (JP)
- Kawasaki Medical School Hospital (JP)
Publication Details
- Journal
- Journal of Pharmaceutical Health Care and Sciences
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1186/s40780-025-00418-5
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00